CDKN2A is a known negative prognostic marker in glioblastoma that frequently undergoes homozygous deletion (between 40% to 60% of the patients). RXcel's smart RNA molecules turn this gene into a therapeutic target which offers a rational for a transformative approach to treatment, laying the foundation for a more precise clinical intervention.
Despite current standard-of-care treatments (surgery, radiotherapy, and temozolomide), median survival for patients with glioblastoma remains just 12 to 15 months. There have been few advances over the past two decades, and recurrence is almost inevitable. Novel, targeted therapies are urgently needed.
Compared to other solid tumors, glioblastoma sees disproportionately low clinical trial activity — despite its severity and poor prognosis. This highlights a major gap in innovation and investment that RXcel is aiming to address.